Skip to main content

Table 2 Treatment effect and complication in study groups

From: Non-invasive duo positive airway pressure ventilation versus nasal continuous positive airway pressure in preterm infants with respiratory distress syndrome: a randomized controlled trial

Characteristic

NDUOPAP

NCPAP

P value

Failure in first 72 h, n (%)

3(4.1%)

6(8.1%)

0.494

Duration of Noninvasive Respiratory support (hr)

(mean± SD)

39.18±18.14

50.12±23.83

0.004

Duration of oxygen therapy (hr)

(mean± SD)

75.48±26.06

107.45±156.06

0.034

Duration of hospitalization (hr)

Mean ± SD)

495.88±310.11

668.08±360.46

0.002

Pneumothorax, n median (IQR)

0(0)

2(2.7)

0.497

IVH, n (%)

Grade I & II

3(4.1)

5(6.8)

0.719

PDA mild, n (%)

4(5.4%)

5(6.8%)

1

PDA moderate, n (%)

4(5.4)

3(4.1)

1

BPD, n (%)

0(0)

1(1.4)

0.319

Apnea, n (%)

1(1.4%)

4(5.4%)

0.366

Deaths, n (%)

2(2.7%)

5(6.8%)

0.442

Surfactant

First dose, n (%)

31(41.9%)

39(52.7%)

0.042

Surfactant

Secondary dose, n (%)

13(17.6%)

20(27%)

0.042

Surfactant

3 dose, n (%)

2(2.7%)

1(1.4%)

0.042

  1. h hour, PDA Patent Ductus Arteriosus, n number, BPD Bronchopulmonary dysplasia, IQR Inter Quartile Range, IVH Intra Ventricular hemorrhage